Impact of GH Measurements on GHD Diagnosis
Launched by UNIVERSITY HOSPITAL, MONTPELLIER · Aug 7, 2020
Trial Information
Current as of May 21, 2025
Completed
Keywords
ClinConnect Summary
The investigators analysed GH provocative test of 41 young patients (median age: 12 years) from Pediatric Department of Montpellier Hospital, (26 boys and 15 girls), admitted for follow-up or for suspicion of growth hormone deficiency. Serum GH of peak concentrations were compared using three automated immunoanalyses : COBAS 8000 e602 (ROCHE Diagnostics), IDS-iSYS (IDS immunodiagnostic systems) and Liaison XL (Diasorin S.A.).
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Age\<18 years, admitted for suspicion (short stature or growth retardation) or follow-up of GHD in pre-and pubertal age
- • patients undergoing insulin-induced hypoglycaemia stimulation test also called insulin tolerance test (ITT)
- * Exclusion criteria:
- • Age \> 18 years
- • Patients undergoing different provocation tests
About University Hospital, Montpellier
The University Hospital of Montpellier is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical trials. Renowned for its commitment to patient-centered care, the hospital collaborates with multidisciplinary teams to explore cutting-edge treatments and therapies across various medical fields. By integrating clinical practice with education and research, the University Hospital of Montpellier aims to enhance health outcomes and contribute to the scientific community's understanding of complex medical conditions. Its robust infrastructure and expertise make it a pivotal player in the landscape of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montpellier, , France
Patients applied
Trial Officials
Manuela Lotierzo, PhD
Principal Investigator
UH MONTPELLIER
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials